Biotech grants in South Korea

Scheduled

Funds two €5M projects to use biotechnology to recycle complex plastics into high-value products at pilot scale across industrial value chains.

Scheduled

Funds €6M projects that turn bio-waste and secondary raw materials into safe, circular products, materials and value chains.

Scheduled

Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.

Scheduled

Funds a €3M coordination action that benchmarks emerging industrial bio-based systems for cleaner, circular and more competitive European value chains.

Scheduled

Funds three €4M research projects that replace hazardous biocidal actives with safer bio-based substances for wood and mosquito control.

Scheduled

Funds a European community and roadmap for trustworthy frontier AI models in healthcare.

Scheduled

Funds two €7–8M innovation projects that move food-system microbiome products from validated testing toward reliable EU-market scale-up.

Scheduled

Funds two projects to use livestock microbiomes for healthier animals, lower antimicrobial use and safer, more sustainable One Health systems.

Between cycles

Invests in scale-up ventures in digital, clean technology, and biotechnology through equity to accelerate commercialization pathways.

Between cycles

Funds innovative SME-led international R&D consortia through the Eurostars Call 12 grant process.

Between cycles

Funds advanced innovation projects advancing robotics and physical AI deep-tech initiatives toward scalable outcomes.

Between cycles

Invests in European deep-tech scale-up ventures with momentum needing capital for commercial expansion.

Between cycles

Supports EIC beneficiaries' participation in major trade fairs across the EU, MENA and the US.

Between cycles

Funds early-stage deep tech startups developing solutions at TRL 4-5 in collaboration with industry partners through a 4-month co-creation programme.

Between cycles

Supports international consortia so small companies can turn joint innovation into export-ready products.

Closed

Pays up to 25 small consortia EUR 200,000 each to test the commercial exploitation potential of results that already came out of earlier Horizon Europe or Horizon 2020 Cluster 4 projects.

Funds clinical trials of prophylactic vaccines against neglected tropical diseases such as schistosomiasis, leishmaniasis and leprosy in sub-Saharan Africa.

Closed

Pays deep-tech start-ups, SMEs and research organisations a €300,000 lump sum in Stage 1, then up to €2.5 million in Stage 2, to push high-risk breakthrough innovations that lack commercial uptake toward real-world, demand-tested deployment.

Closed

Funds early clinical trials of therapies built from the molecules cells secrete rather than the cells themselves, aiming for an off-the-shelf alternative to cell therapy.

Funds research into biomanufactured alternatives to imported natural rubber and fossil-based synthetic rubber for automotive, healthcare and industrial uses.

Funds research into bio-based, biodegradable delivery coatings for fertilisers that replace today's microplastic-shedding polymer coatings.

Funds a full-scale biorefinery that produces bio-based drop-in platform chemicals able to compete directly with their fossil-based equivalents.

Closed

Funds biodiscovery projects that use AI and digital tools to find and sustainably produce new natural compounds from marine and freshwater organisms.

Closed

Funds companies discovering and scaling up bioactive natural compounds from land-based organisms for pharma, cosmetics, food and other markets.